To evaluate the clinical and functional activity of patients with rheumatoid arthritis at one and two years after starting anti-TNF therapy.
Patients and methods
This is a retrospective study of 50 RA patients, who started ANTI-TNF theraphy between June 2006 and july 2009. The main variables in the study were: DAS28, HAQ and pain VAS. We analyzed evolution after 1 year and 2 years from the beginning of the treatment. The comparison with the basal state was made with Student's t test. The statistical study was analyzed by the SPSS 18,0.
Results
The study includes 50 patients, 66% female, with RF in 76% and erosions in 64%, treated with etanercept (28), adalimumab (13) and infliximab (9). Most of them (70%) had recieved at least 2 FAMES before biological. In the below table we compare changes in clinical parameters for different biologics after one and two years.
Conclusions
All anti-TNF significantly improve disease activity, functional status and pain VAS after the first year. This improvement continues but not significantly increases the second year.
Rheumatology Unit, Valme University Hospital, Sevilla, Spain HAQ -Etanercept 1,61 ± 0,61 0,77 ± 0,64 (p <0,005) 0,80 ± 0,73 (p = 0,87) -Adalimumab 1,63 ± 0,58 1,35 ± 0,63 (p = 0,05) 1,38 ± 0,70 (p =0,58) -Infliximab 1,45 ± 0,74 1,24 ± 0,72 (p = 0,20) 1,28 ± 0,69 (p = 0,34)
